Vertex Pharmaceuticals Profit Margin

The latest profit margin for VRTX is 35.0% as of June 2026. That compares with 31.86% in the prior-year period — up 9.9% year over year. That is above the Healthcare sector average of 9.71%. Investors often review this figure alongside Vertex Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, VRTX's profit margin moved from 31.86% to 35.0% — a 9.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vertex Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, VRTX currently prints 35.0% for profit margin, while the sector average sits near 9.71%. That is roughly 260.6% above the sector mean. Large gaps often invite a closer look at Vertex Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Vertex Pharmaceuticals converts resources into returns. At 35.0%, VRTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 31.86% in the prior-year period — up 9.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VRTX's profit margin (35.0%), review year-over-year change from 31.86%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.